title: Evaluation of extended interval dosing aminoglycosides in the morbidly obese population.
abstract: Aminoglycoside dosing has been studied in the obese population, typically recommending an adjusted weight utilizing a 40% dosing weight correction factor (IBW + 0.4 × (TBW-IBW)). These studies included limited numbers of morbidly obese patients and were not done in the era of extended interval aminoglycoside dosing. Here, we report a retrospective evaluation of morbidly obese patients receiving gentamicin or tobramycin at our hospital. The objective of this study was to evaluate the accuracy of the commonly recommended adjusted weight for weight-based dosing. There were 31 morbidly obese patients who received gentamicin or tobramycin 5-7 mg/kg every 24 hours using a 40% dosing weight correction factor. Our institution utilizes 16-hour postdose concentrations to monitor extended interval aminoglycosides. Twenty-two of the 31 patients (71%) achieved an appropriate serum drug concentration. Four patients (13%) were found to be supratherapeutic and 5 patients (16%) subtherapeutic. The only variable that correlated with supratherapeutic levels was older age (P = 0.0378). Our study helps to validate the current dosing weight correction factor (40%) in the morbidly obese population. We recommend caution when dosing aminoglycosides in morbidly obese patients who are of older age.
authors.affiliation: Department of Pharmacy, Jewish Hospital, 200 Abraham Flexner Way, Louisville, KY 40202, USA.
authors.forename: Ashley L
authors.initials: AL
authors.lastname: Ross
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Tharp
authors.forename: Gerald R
authors.initials: GR
authors.lastname: Hobbs
authors.forename: Richard
authors.initials: R
authors.lastname: McKnight
authors.forename: Aaron
authors.initials: A
authors.lastname: Cumpston
references.citation: Pharmacotherapy. 2007 Aug;27(8):1081-91
references.pmid: 17655508
references.citation: Ann Pharmacother. 2007 Oct;41(10):1734-9
references.pmid: 17726066
references.citation: Am J Respir Crit Care Med. 2004 Jun 15;169(12):1332; author reply 1333
references.pmid: 15187012
references.citation: Eur J Clin Pharmacol. 1983;24(5):643-7
references.pmid: 6873144
references.citation: Intensive Care Med. 2004 Jan;30(1):18-32
references.pmid: 14625670
references.citation: Clin Infect Dis. 1997 Jul;25(1):112-8
references.pmid: 9243045
references.citation: Am J Med. 1998 Sep;105(3):182-91
references.pmid: 9753020
references.citation: Clin Pharmacokinet. 1993 Aug;25(2):103-14
references.pmid: 8403734
references.citation: Antimicrob Agents Chemother. 1995 Feb;39(2):545-8
references.pmid: 7726530
references.citation: Am J Hosp Pharm. 1981 Jun;38(6):841-4
references.pmid: 7246555
references.citation: Clin Pharmacokinet. 2000 May;38(5):415-26
references.pmid: 10843460
references.citation: Ann Pharmacother. 1998 Dec;32(12):1275-83
references.pmid: 9876806
references.citation: Contrib Nephrol. 2006;151:184-202
references.pmid: 16929142
references.citation: Am J Med. 1988 Jun;84(6):1053-60
references.pmid: 3376975
references.citation: Kidney Int. 2006 Nov;70(9):1636-41
references.pmid: 16955108
references.citation: Trans R Soc Trop Med Hyg. 2000 Jul-Aug;94(4):425-8
references.pmid: 11127249
references.citation: J Clin Pharmacol. 1981 Jul;21(7):288-93
references.pmid: 7263927
references.citation: J Pharm Sci. 1999 Jan;88(1):1-7
references.pmid: 9874695
references.citation: Cancer Chemother Pharmacol. 1989;25(2):139-42
references.pmid: 2557169
references.citation: J Infect Dis. 1978 Oct;138(4):499-505
references.pmid: 712111
references.citation: Antimicrob Agents Chemother. 2011 Sep;55(9):4006-11
references.pmid: 21670189
references.citation: Antimicrob Agents Chemother. 1982 Apr;21(4):575-80
references.pmid: 7081978
references.citation: Orthopedics. 2006 Nov;29(11):984-8
references.pmid: 17134048
references.citation: Antimicrob Agents Chemother. 1995 Mar;39(3):650-5
references.pmid: 7793867
references.citation: Clin Pharmacokinet. 2000 Sep;39(3):215-31
references.pmid: 11020136